Latest

Latest AstraZeneca News | Page 4

  • Latest AstraZeneca news stories and updates. What is happening today? All recent AstraZeneca news and developments. Live coverage and timeline of AstraZeneca. All you need to know about AstraZeneca.
Enhertu showed clinically meaningful and durable responses across multiple HER2-expressing tumour types in DESTINY-PanTumor02 Phase II trial
Update on US regulatory review of Lynparza in combination with abiraterone for metastatic castration-resistant prostate cancer
Haven’t had COVID or a vaccine dose in the past six months? Consider getting a booster
TGA Product Information safety updates 31 January
How common are severe side effects from COVID vaccines? And how are they detected?
TGA Product Information safety updates 21 December
Preoperative immunotherapy for mesothelioma shows favorable outcomes
Datopotamab deruxtecan showed promising responses as monotherapy and in combination with Imfinzi
Datopotamab deruxtecan showed encouraging and durable efficacy in patients with heavily pretreated HR-positive
Camizestrant significantly delayed disease progression in advanced ER-positive breast cancer
Capivasertib plus Faslodex reduced risk of disease progression or death by 40% versus Faslodex
TGA Product Information safety updates
Enhertu achieved statistically significant overall survival, reducing risk of death by 36% vs. trastuzumab emtansine
AstraZeneca showcases strength of haematology portfolio and pipeline across multiple hard-to-treat conditions
AstraZeneca announces sale of its West Chester, Ohio manufacturing site
AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy
AstraZeneca aims to redefine breast cancer care with new data across treatment spectrum at SABCS 2022
Thousands of Tasmanian devils are dying from cancer – but a new vaccine approach could help us save them
AstraZeneca ranked in top three in Access to Medicine Index
Enhertu recommended for approval in EU by CHMP for patients with previously treated HER2-positive advanced gastric cancer
Imfinzi plus chemotherapy recommended for approval in EU by CHMP as first immunotherapy regimen for advanced biliary tract cancer
Lynparza in combination with abiraterone recommended for approval
AstraZeneca expands global footprint in rare disease with availability of first Alexion rare disease therapy for patients
Imfinzi and Imjudo with chemotherapy approved in US for patients with metastatic non-small cell lung cancer
Previous COVID infection may not protect you from new subvariant wave. Are you due for booster
Previous COVID infection may not protect you from new subvariant wave
Year-to-date and Q3 2022 results
PT027 recommended by FDA advisory committee as new rescue treatment for asthma
Farxiga improved symptom burden and health-related quality of life
AstraZeneca presents data at ASN Kidney Week 2022 reinforcing urgent need for early screening of chronic kidney disease and benefits
Beyfortus approved in EU for prevention of RSV lower respiratory tract disease in infants
AstraZeneca funds R&D Postdoctoral Challenge finalists
Vaxzevria receives full Marketing Authorisation in EU for prevention of Covid
AstraZeneca advances scientific leadership in cardiovascular and renal diseases with over 60 abstracts collectively
Camizestrant significantly improved progression-free survival in advanced ER-positive breast cancer
Capivasertib Phase III trial met primary endpoints
Update on MESSINA Phase III trial for Fasenra in eosinophilic esophagitis
Imjudo in combination with Imfinzi approved in US for patients with unresectable liver cancer
Budding pathologist untangling Covid vaccine response
IDWeek data reinforces AstraZeneca’s commitment to advance science in vaccines and immune therapies
Illumina and AstraZenca team up on AI-based research project
Myocarditis seven times more likely with Covid than vaccines
Alexion aims to advance NMOSD treatment landscape with exceptional Ultomiris efficacy data at ECTRIMS 2022
How should we manage COVID without rules?
Pollen does more than make you sneeze
Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type1
Tezspire approved in Japan for treatment of severe asthma
Ultomiris approved in Europe for treatment of adults with generalised myasthenia gravis

© 2024 - The National Tribune Australia